Theravance Biopharma (TBPH) Director Susannah Gray Sells Shares in Merger

What Happened

• Susannah Gray, a director of Theravance Biopharma (TBPH), reported dispositions on Sept. 23, 2026 tied to the company’s merger with Zymeworks. The Form 4 shows a total of 164,088 ordinary shares and derivative awards were cancelled/converted at the merger effective time and converted into merger consideration. Per the merger agreement, each ordinary share was converted into $17.00 in cash plus one contingent value right (CVR). The cash component totals approximately $2,789,496; CVRs are non-tradeable contingent rights to potential future cash based on specified commercial milestones.
• These were not open-market sales but involuntary dispositions under the merger agreement (transaction code D).

Key Details

• Transaction date: 2026-09-23 (filed on Form 4: 2026-09-24). Filing appears timely.
• Shares/awards disposed: 42,137; 6,009; 32,666 (derivative); 22,044 (derivative); 23,576 (derivative); 24,258 (derivative); 13,398 (derivative) — total 164,088.
• Per-share cash consideration: $17.00; total cash ≈ $2,789,496. In addition, one CVR was issued per share/underlying share of awards.
• Footnotes: F1–F3 explain the Merger Agreement conversions — ordinary shares, RSUs and options were cancelled and converted into cash (and CVRs); RSU cash amounts subject to required tax withholdings.
• Shares owned after transaction: the filing indicates the insider’s ordinary shares and listed awards were converted/cancelled under the merger; holdings now consist of the cash paid and CVRs (no remaining ordinary shares reported).

Context

• These dispositions resulted from the company becoming a wholly owned subsidiary of Zymeworks under the merger agreement, not from discretionary open-market selling. The CVRs are contractual, non-tradable contingent rights that may pay additional cash if specified commercial milestones are met.
• For retail investors: merger-driven conversions are routine corporate events. They reflect deal consideration, not an independent signal of insider sentiment through market buying or selling.